OTCM
SGFEF
Market cap3.80bUSD
Oct 31, Last price
104.61USD
Name
Siegfried Holding AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Siegfried Holding AG is a global enterprise active in the life sciences industry. The company is dedicated to developing and manufacturing active pharmaceutical ingredients (APIs) and their intermediate compounds, as well as a diverse range of finished drug products. These include solid oral medications, sterile and aseptically filled injectable solutions, ophthalmic preparations, and inhalable treatments. It offers extensive contract development and manufacturing (CDMO) services, which span pharmaceutical and analytical development, process and analytical transfer, commercial-scale production and packaging, and the provision of materials for clinical trials along with process scale-up. Siegfried also supplies specific APIs and controlled substances, particularly those used in anesthetics, pain relief, and treatments for central nervous system and respiratory conditions. Furthermore, the company licenses solid oral and sterile pharmaceutical products, meticulously prepares registration dossiers, and provides common technical documents for various offerings. Founded in 1873, Siegfried Holding AG is headquartered in Zofingen, Switzerland.
Related entities
Subsidiaries (14)
Alliance Medical Products, Inc.
Siegfried AG
SIEGFRIED BARBERA S.L.
Siegfried Deutschland Holding GmbH
SIEGFRIED EL MASNOU S.A.
Siegfried Evionnaz SA
Siegfried Hameln GmbH
Siegfried Hong Kong Limited
SIEGFRIED MALTA LIMITED
Siegfried PharmaChemikalien Minden GmbH
Siegfried St. Vulbas SAS
Siegfried USA Holding, Inc.
Siegfried USA, LLC
SIEGFRIED DiNAMIQS AG
Key people
Marcel Imwinkelried
Chief Executive Officer, Member of the Executive Committee · since 2024
Independent Non-Executive Vice Chairman of the Board of Directors · since 2020
Olesia Silanteva
Chief Human Resources Officer, Member of the Executive Committee · since 2025
Stefan Randl
Chief Scientific Officer, Member of the Executive Committee · since 2025
Peter Freisler
Chief Business Officer, Member of the Executive Committee · since 2025
Henrik Krupper
Chief Operating Officer - Drug Substances, Member of the Executive Committee · since 2023
Marianne Spaene
Chief Business Officer, Member of the Executive Committee · since 2010
Chief Financial Officer, Member of the Executive Committee · since 2024
Luca Dalla Torre
Chief Legal and Sustainability Officer, Member of the Executive Board · since 2025
Independent Non-Executive Chairman of the Board of Directors · since 2014
Alexandra Brand
Non-Executive Independent Member of the Board of Directors · since 2022
Wolfram Carius
Non-Executive Independent Member of the Board of Directors · since 2014
Elodie Carr-Cingari
Non-Executive Independent Member of the Board of Directors · since 2023
Non-Executive Independent Member of the Board of Directors · since 2022
Isabelle Welton
Non-Executive Independent Member of the Board of Directors · since 2020
Headquarters & legal address
Untere Brühlstrasse 4
Zofingen, AG 4800
CH
Zofingen, AG 4800
CH
Other language
Siegfried Holding Ltd
Other language
Siegfried Holding SA
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||